The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Continues to Advance R&D Capabilities
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Dev…
CSL Media Statement
CSL statement in response to media reports on case against Joseph Chiao
CSL Limited Celebrates 25 Years on the ASX
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange …
$2.5 million CSL Centenary Fellowships announced
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatm…
CSL to Move Global Headquarters
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbour…
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Renews Partnership with NYSF
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a n…
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
